USD0.000æéå€ååŒÂ  (ET)
8.22BæäŸ¡ç·é¡
52.69çŽè¿12ã¶æPER
äž»èŠããŒã¿
49.630å§å€
49.830é«å€
1.62Måºæ¥é«
52.69çŽè¿12ã¶æPER
54.53äºæ³PER
--çŽè¿12ã¶æé
åœ
0.97%売買å転ç
50.030忥çµå€
48.520å®å€
59.71M売買代é
22.36æ ªäŸ¡åçç
4.54PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
4.82%ç·è³ç£å©çç
40.79052é±é«å€
0.68åºæ¥é«æ¯ç%
367.07MçŽå©ç
167.54Mæ ªåŒæ°
0.92981æ ªåœããå©çïŒEPSïŒ
0.31ããŒã¿å€
9.36%èªå·±è³æ¬å©çç
25.16552é±å®å€
2.62%æ¯ãå¹
75.67%ç²å©çç
8.22BæäŸ¡ç·é¡
-3.73ãªã¹ã¯ãªã¿ãŒã³
2.23%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Alkermes Plcã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž25äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯55.10ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Alkermes Plcã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Alkermes Plcã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Alkermes Plc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Ionis Pharmaceuticals Inc
IONS
25
ææšî
ææš
売ã(4)
äžç«(2)
è²·ã(0)
ç§»åå¹³å
売ã(3)
äžç«(0)
è²·ã(3)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Alkermes Plcã®äŒæ¥æ
å ±î
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
äŒæ¥ã³ãŒãALKS
äŒæ¥åAlkermes Plc
æé«çµå¶è²¬ä»»è
ãCEOãPops (Richard F)
ãŠã§ããµã€ãhttps://www.alkermes.com/
æ ªäž»çµ±èšî
ãããã質å
Alkermes PlcïŒALKSïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îAlkermes PlcïŒALKSïŒã®çŸåšã®æ ªäŸ¡ã¯48.99ã§ãã
Alkermes Plcã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îAlkermes Plcã®ãã£ãã«ãŒã·ã³ãã«ã¯ALKSã§ãã
Alkermes Plcã®52é±é«å€ã¯ãããã§ããïŒ
îAlkermes Plcã®52é±é«å€ã¯40.79ã§ãã
Alkermes Plcã®52é±å®å€ã¯ãããã§ããïŒ
îAlkermes Plcã®52é±å®å€ã¯25.16ã§ãã
Alkermes Plcã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îAlkermes Plcã®æäŸ¡ç·é¡ã¯8.21Bã§ãã
Alkermes Plc (ALKS) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãAlkermes PlcïŒALKSïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯55.10ã§ãã
Alkermes Plc (ALKS) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îAlkermes PlcïŒALKSïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯1.47ã§ãã